Fierce Biotech Names HiFiBiO TherapeuticsHiFiBiO Therapeutics a “Fierce 15” Biotech Company of 2023

28 Aug 2023
www.biospace.com
ImmunotherapyPhase 1
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- HiFiBiO Therapeutics, a clinical stage global biotech company focusing on improving patient lives with single cell precision, today announced that Fierce Biotech has named it as one of 2023’s “Fierce 15” biotechnology companies. The annual special report features the most innovative and promising early-stage biotechnology companies in the industry. This press release features multimedia. View the full release here: “HiFiBiO TherapeuticsHiFiBiO Therapeutics is at the forefront of harnessing single-cell insights to bring innovative immunomodulatory therapeutics into the clinic,” remarked Liang Schweizer, PhD, Founder, Chairperson, and CEO of HiFiBiO TherapeuticsHiFiBiO Therapeutics. “The Fierce 15 recognition reflects our passionate dedication to patients with unmet medical needs, and further highlights our unique Drug Intelligence Science (DIS®) approach to enhance the probability of success of immunotherapy from targets to drugs to patients.” HiFiBiO TherapeuticsHiFiBiO Therapeutics is differentiated by its pioneering DIS® approach which combines a proprietary microfluidic single-cell platform with advanced AI/ML-based data analytics to gain unprecedented insights into human disease biology. Through this high-resolution translational approach, HiFiBiO Therapeutics has advanced three programs into Phase 1 trials, a first-in-class TNFR2 agonistTNFR2 agonist (HFB200301, NCT05238883), a best-in-class BTLA antagonist (HFB200603, NCT05789069), and a 2nd generation OX40 agonistOX40 agonist (HFB301001, NCT05229601). Since 2017, HiFiBiO TherapeuticsHiFiBiO Therapeutics has built a sustainable pipeline targeting key mechanisms of immune modulation, with eight clinical candidates discovered, mainly across oncology and autoimmune diseases. With more than $180M in financing from world-class investors and an experienced top-tier scientific and clinical team, HiFiBiOHiFiBiO is well-positioned to deliver effective therapeutic solutions for patients globally. “For the past 21 years, we have assessed hundreds of early-stage companies for inclusion in the 'Fierce 15' special report. To curate this list, we consider a diverse range of factors, including the robustness of their technology, partnerships, venture support and their competitive positioning within the market,” said Ayla Ellison, Editor-in-Chief, Fierce Life Sciences and Healthcare. “Our special report celebrates innovation and creativity in the face of intense competition.” About Fierce Biotech Fierce Biotech is the biotech industry’s daily monitor, providing the latest news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 300,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day’s top stories. About HiFiBiO TherapeuticsHiFiBiO Therapeutics HiFiBiO TherapeuticsHiFiBiO Therapeutics is a clinical stage global biotech pioneering a unique high-resolution translational solution (DIS®, Drug Intelligence Science) to enhance the probability of success for immunotherapies. DIS® combines unique single cell capabilities with AI/ML approaches using patient samples to discover novel targets, effective antibody drugs, and predictive biomarkers. With DIS®, HiFiBiOHiFiBiO gains an unprecedented understanding of immune modulation in human diseases which drives a robust clinical pipeline of transformative immunotherapies. Additionally, HiFiBiOHiFiBiO has partnered with major multinational pharmaceutical and biotech companies applying its innovative DIS® approach. Additional information can be found at . HiFiBiO TherapeuticsHiFiBiO Therapeutics, HiFiBiO TherapeuticsHiFiBiO Therapeutics logo, and DIS® are trademarks of HiFiBiOHiFiBiO and its affiliates. View source version on businesswire.com: Contacts Media Vincent Tse Senior Director of Staff and Strategy HiFiBiO Therapeutics media@hifibio.com Source: HiFiBiO TherapeuticsHiFiBiO Therapeutics Smart Multimedia Gallery Photo View this news release and multimedia online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.